PCSK9 and HMG-CoA Reductase Inhibitor Reduce Breast Cancer Risk: Mendelian Randomization Evidence of Metabolic Mediation

This attachment includes three supplementary tables, which present detailed data from the Mendelian randomization analysis. Refer to the main text for specific methods.Table S1 : Significant SNPs for PCSK9 and HMG-CoA reductase;Table S2 : Effect of PCSK9/HMG CoA reductase inhibitor on CHD;Table S3 : Effect of PCSK9/HMG CoA reductase inhibitor on circulating metabolites and breast cancer.